We are very pleased to update you on our latest progress and some significant upcoming milestones.
As you may know, we recently announced that ACT was granted EU orphan medicinal product designation for our retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) for the treatment of Stargardt’s Macular Dystrophy (SMD).
Additionally, we also announced that the first patients had been enrolled at the Jules Stein Eye Institute at UCLA for our two upcoming Phase 1/2 clinical trials using hESC-derived RPE cells for Stargardt’s disease and Dry Age-Related Macular Degeneration (Dry AMD). They are finishing the testing and pre-surgical preparations on these patients currently, and the surgeries are scheduled for the second week in July.
We hope you will continue to check in with us at this exciting time to learn more about ACT’s latest developments and our clinical progress.
Interim Chairman and CEO
Advanced Cell Technology, Inc.